In a welcome move, Disc Medicine saw its Relative Strength Rating rise from 66 to 71 on Tuesday.
How To Invest In Stocks In Both Bull And Bear Markets
This exclusive rating from Investor's Business Daily tracks share price movement with a 1 (worst) to 99 (best) score. The score shows how a stock's price performance over the last 52 weeks stacks up against all the other stocks in our database.
Decades of market research shows that the stocks that go on to make the biggest gains often have an 80 or better RS Rating as they launch their biggest climbs. See if Disc Medicine can continue to rebound and clear that threshold.
While Disc Medicine is not near an ideal entry right now, see if it goes on to form and break out of a proper chart pattern.
The company showed 0% earnings growth in its most recent report, while sales growth came in at 0%.
The company holds the No. 210 rank among its peers in the Medical-Biomed/Biotech industry group. Aurinia Pharmaceuticals, Halozyme Therapeutics and argenx ADR are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
